3E8C
Crystal structures of the kinase domain of PKA in complex with ATP-competitive inhibitors
Summary for 3E8C
Entry DOI | 10.2210/pdb3e8c/pdb |
Related | 3E87 3E88 3E8D 3E8E |
Descriptor | cAMP-dependent protein kinase catalytic subunit alpha, cAMP-dependent protein kinase inhibitor peptide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-{[(2R)-2-amino-3-phenylpropyl]oxy}-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol, ... (4 entities in total) |
Functional Keywords | pka, akt2, kinase, pki, bovine, inhibitor, atp-binding, camp, lipoprotein, myristate, nucleotide-binding, nucleus, phosphoprotein, serine/threonine-protein kinase, transferase, protein kinase inhibitor |
Biological source | Bos taurus (cow) More |
Cellular location | Cytoplasm : P00517 |
Total number of polymer chains | 12 |
Total formula weight | 260845.93 |
Authors | Concha, N.O.,Elkins, P.A.,Smallwood, A.,Ward, P. (deposition date: 2008-08-19, release date: 2008-11-18, Last modification date: 2024-10-30) |
Primary citation | Rouse, M.B.,Seefeld, M.A.,Leber, J.D.,McNulty, K.C.,Sun, L.,Miller, W.H.,Zhang, S.,Minthorn, E.A.,Concha, N.O.,Choudhry, A.E.,Schaber, M.D.,Heerding, D.A. Aminofurazans as potent inhibitors of AKT kinase Bioorg.Med.Chem.Lett., 19:1508-1511, 2009 Cited by PubMed Abstract: AKT inhibitors containing an imidazopyridine aminofurazan scaffold have been optimized. We have previously disclosed identification of the AKT inhibitor GSK690693, which has been evaluated in clinical trials in cancer patients. Herein we describe recent efforts focusing on investigating a distinct region of this scaffold that have afforded compounds (30 and 32) with comparable activity profiles to that of GSK690693. PubMed: 19179070DOI: 10.1016/j.bmcl.2009.01.002 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.2 Å) |
Structure validation
Download full validation report
